Back to Directory
Laronidase
Performance & EnduranceEnzyme replacement therapy for MPS I, recombinant protein for rare disease.
Key Benefits
- ✓Treats MPS I
- ✓Enzyme replacement
- ✓Improves respiratory function
- ✓Reduces liver/spleen size
- ✓Improves mobility
Dosing Information
Dosage Range
0.58 mg/kg
Frequency
Once weekly IV
Typical Duration
Lifelong
Detailed Protocol
Administered via intravenous infusion weekly. Premedication recommended. Hospital or infusion center. Lifelong therapy. Prescription only.
About Laronidase
Laronidase (Aldurazyme) is recombinant human alpha-L-iduronidase for enzyme replacement therapy in mucopolysaccharidosis I (MPS I). While technically an enzyme protein, it is peptide-based. FDA-approved for this rare lysosomal storage disease.
Research Notes
FDA-approved in 2003 for MPS I (Hurler syndrome). First ERT for this condition. Significantly improves outcomes but does not cross BBB. Lifelong treatment required.
Potential Side Effects
- •Infusion reactions common
- •Antibody formation
- •Flushing
- •Fever
- •Requires monitoring
Always consult with a healthcare professional before starting any peptide therapy.